PMV Pharmaceuticals, Inc.

NASDAQ: PMVP · Healthcare · Biotechnology

PublicHQ Princeton, NJ · MercerCIK 0001699382Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 45DQ —GM —SS 47

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$77.7M

Employees

as of 2026-09-17

Market cap

$76.3M

as of 2026-09-17

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$77.7M-$77.7M2025

Operating income-$86.2M-$86.2M2025

Total assets$116.6M$116.6M2025

Liabilities$11.8M$11.8M2025

Equity$104.7M$104.7M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is PMV Pharmaceuticals, Inc.’s financial profile?

PMV Pharmaceuticals, Inc. earned -$77.7M in FY2025 net income.

Peers · Healthcare

Adicet Bio, Inc.——Oncolytics Biotech Inc.——Telomir Pharmaceuticals, Inc. Common Stock——RetinalGenix Technologies Inc.——Acrivon Therapeutics, Inc. Common Stock——Cingulate Inc.——

Neighbors

Mercer →

Bristol-Myers Squibb Company$48.2B85A Clearway Energy, Inc.$1.4B54D Essential Properties Realty Trust, Inc.$561.2M71B Miami International Holdings, Inc. $1.4B43D UroGen Pharma Ltd.$109.8M55C Kardigan, Inc.$0——

Key facts

CEODavid H. Mack

SectorHealthcare

IndustryBiotechnology

HeadquartersPrinceton, NJ

ExchangeNASDAQ: PMVP

Employees54

IPO date2020-09-25

Latest filings

8-K2026-09-02 8-K2026-08-31 8-K2026-08-14 10-Q2026-08-14 8-K2026-06-05 8-K2026-05-12 10-Q2026-05-12 DEF 14A2026-04-22

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.